ARCT - Arcturus Therapeutics completes first three dose escalation cohorts in early-stage ARCT-810

Arcturus Therapeutics Holdings (ARCT) completes the first three dose escalation cohorts in its ongoing Phase 1 study with ARCT-810, the messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase ((OTC)) deficiency. The ARCT-810 Phase 1 study is a double blind, placebo-controlled, dose-escalation trial in healthy adult volunteers. The fourth cohort is expected to complete this quarter. The study is designed to evaluate safety and tolerability, and pharmacokinetics, as primary and secondary endpoints. All subjects in cohorts up to 0.3 mg/kg have completed dosing and all study visits. Based on the available preliminary study data, ARCT-810 has been well tolerated at these doses, which are all within the anticipated therapeutic range.All adverse events observed have been mild or moderate and there have been no serious adverse events. The company plans to report final data following study completion is this quarter.

For further details see:

Arcturus Therapeutics completes first three dose escalation cohorts in early-stage ARCT-810